Across TCGA pan-cancer cohorts, PAK3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PAK3 data layer compared with 22 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PAK3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PAK3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.
PDAC and GBM are the cancer types where PAK3 mass-spec protein most reproducibly stratifies survival.